| Symbol | IVA |
|---|---|
| Name | INVENTIVA S.A. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 50 RUE DE DIJON, DAIX, 21121, France |
| Telephone | +33 380447500 |
| Fax | — |
| — | |
| Website | https://www.inventivapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001756594 |
| Description | Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the companys operations are in France. Additional info from NASDAQ: |
Inventiva annonce le Remboursement des Prêts BEI, le Rachat dune partie des BSA BEI etlémission des deux premières tranches dans le cadre du Nouveau Financement
Read moreInventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Read moreInventiva annonce le Remboursement des Prêts BEI, le Rachat dune partie des BSA BEI et lémission des deux premières tranches dans le cadre du Nouveau Financement
Read moreInventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Read moreInformation relative au nombre total de droits de vote etd’actions composant le capital social au 22 mai 2026
Read moreAssemblée Générale Mixte du 30 juin 2026 -Modalités de mise à disposition des documents préparatoires
Read moreCombined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Read moreStatement of Total Voting Rights and Shares Forming TheCompany’s Share Capital as of May 22, 2026
Read moreStatement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026
Read moreCombined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Read more